Abstract
Objective: The most common cause of treatment failure in patients with ovarian cancer is recurrence and dissemination in the peritoneal cavity, and treatment results of patients with disseminated disease are disappointed with a 5-year survival rate of only 30%. For this reason intraperitoneal (IP) delivery of chemotherapy is introduced as a new treatment option; however, the results of IP chemotherapy are still debatable because of catheter-related and IP infusion-related complications. We sought to determine whether intraoperative intraperitoneal (IP) chemotherapy with paclitaxel improves PFS and OS among patients with epithelial ovarian cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
